Eton Pharmaceuticals, Inc.
Key Metrics
How this company measures up on the fundamentals that matter
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Valuation
Trading at $30 against a fair value of $56, a 47% discount. Passes all ethical screens. Ranks better than 94% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Market Data
Trading characteristics and market positioning
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Analyst Coverage
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | RIEDEL NORBERT G | Director | 32,155 | $260,605 | |
| 2026-02-03 | RIEDEL NORBERT G | Director | 30,000 | $132,600 | |
| 2025-08-20 | GRUBER JAMES R | Chief Financial Officer | 41,713 | $673,714 | |
| 2025-06-16 | KREMPA DAVID | Officer | 34,000 | $504,318 | |
| 2025-06-10 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 7,930 | $125,484 | |
| 2025-06-05 | BRYNJELSEN SEAN E | Chief Executive Officer | 210,000 | $3,592,611 | |
| 2025-01-03 | RIEDEL NORBERT G | Director | 102,400 | $373,842 | |
| 2024-10-23 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 10,000 | $79,814 | |
| 2024-10-08 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 62,070 | $434,137 | |
| 2024-09-11 | OPALEYE MANAGEMENT, INC. | Beneficial Owner of more than 10% of a Class of Security | 107,500 | $504,875 |
What If You'd Bought ETON?
| Period | Price Then | Price Return | Divs/Share | $1,000 Became | Total Return |
|---|---|---|---|---|---|
| 1 Month | $29.84 | +5.5% | — | $1,055 | +5.5% |
| 2 Months | $26.36 | +19.5% | — | $1,195 | +19.5% |
| 3 Months | $19.02 | +65.6% | — | $1,656 | +65.6% |
| 6 Months | $16.88 | +86.6% | — | $1,866 | +86.6% |
| 1 Year | $15.71 | +100.5% | — | $2,005 | +100.5% |
| 2 Years | $3.60 | +774.7% | — | $8,747 | +774.7% |
| 3 Years | $3.87 | +713.7% | — | $8,137 | +713.7% |
| 5 Years | $6.79 | +363.8% | — | $4,638 | +363.8% |
Historical returns. Past performance does not guarantee future results. Prices from market close data.
Framework Review History
Timestamped framework reads — tracking how the analysis evolves over time
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with near-perfect ethical score (97). The risk-adjusted return profile shows excellent risk-adjusted returns.
Latest Analysis — ETON
Timestamped intelligence from our daily research pipeline
Eton Pharmaceuticals (ETON) — Markup at $29.13 with 97.4 Ethical Score body { background: #0a0e14; color: #e0e0e0; font-family: 'Segoe UI', Arial, sans-serif; margin: 0; padding: 0; line-height: 1.7; } .container...
Titan Macro Desk | Economic Calendar The Week That Sets Q3: China PMI, Eurozone Inflation, and ISM Manufacturing 29 June – 3 July 2026 • Holiday-Shortened Week • First Q3...
Titan Macro Desk | Earnings Preview Nike's Insider Signal, Defence Earnings, and 42 Reports That Set Q3's Tone Week of 30 June – 3 July 2026 • Holiday-Shortened Week •...
Breaking Analysis Vance Says Iran Deal Has a "Very Good Foundation" and Crude Just Broke $70. What Changed Overnight. Titan Macro Desk • 25 June 2026 • titanprotect.trade The Shift...
FX Focus: The Dollar Rallied While Every Safe Haven Failed, and USDJPY at 161.60 Is a Loaded Gun Titan FX Desk — Alpha Insights — Tuesday 23 June 2026 FX...
Nikkei Crashed 5.3% While FTSE Barely Flinched: The Global Fracture Widens Titan Global Desk — Alpha Insights — Tuesday 23 June 2026 Nikkei Crashed 5.3% While FTSE Barely Flinched: The...
ALPHA INSIGHTS Tuesday 23 June 2026 | Post-Close read NAS100 Broke 29,500 While the Dow Held 51,665: Every Level That Matters Now Setup Radar | Titan Technical Desk The NAS100...
GBP/USD (Cable) — Daily Framework Read | Thursday 18 June 2026 Titan Macro Desk | Daily Framework Read Cable closed Thursday at 1.3196, down 1.72 percent. The Bank of England...
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15